Login to Your Account



Other News To Note


Monday, July 25, 2011
BrainStorm Cell Therapeutics Inc., of New York, inked a deal with PharmaNet LLC, of Princeton, N.J., to assist in developing the protocol and investigational new drug application file for amyotrophic lateral sclerosis (ALS) trials involving the NurOwn technology. NurOwn is based on the use of adult human mesenchymal stem cells and has orphan drug designation in ALS.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription